All In Biotech

Drug Trial Radar · NCT06496581

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

A Randomized Phase III Trial Evaluating the Efficacy and Safety of Standard of Care +/- 177Lu-PSMA617 in de Novo Metastatic Hormone-sensitive Prostate Cancer Patients Having a PSA≥0.2 ng/mL at 6-8 Months After Systemic Treatment Initiation

Last checked: Nov 20, 2026Latest source record: Dec 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Sep 12, 2024

Primary completion

Feb 1, 2033

Study completion Aug 1, 2039

Sponsor

Lead sponsor
UNICANCERAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Novartis
First posted
Jul 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PEACE-6 Poor Responders is an international, multicenter, open-label, controlled, randomized, phase III trial to evaluate the efficacy and safety of 177Lu-PSMA-617 when administered on top of the ongoing standard systemic treatment compared to standard systemic treatment alone in patients with de novo metastatic hormone-sensitive prostate cancer (mHSPC) who do not present with a satisfactory response characterized by a serum prostatic specific antigen (PSA) level of ≥ 0.2 ng/mL at 6 to 8 months after systemic treatment initiation for mHSPC (i.e. poor responders) in the absence of evidence of cancer progression (including a rising PSA level).

Conditions

  • Prostate Cancer Metastatic

Interventions

  • 177Lu-PMSA-617Drug

    Once every 6 weeks, 7400 MBq 177Lu-PMSA-617 will be administered for up to a total of 4 cycles.

  • Standard of CareDrug

    ADT, abiraterone and each ARSI (Apalutamide, Darolutamide, Enzalutamide) will be administrated according to the standard of care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS)Time frame: From randomization to death due to any cause, up to 8.5 years
  2. Radiographic progression-free survival (rPFS)Time frame: From randomization to radiographic progression or death, up to 8.5 years

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Institut de Cancérologie de l'Ouest

    Angers, France · Not yet recruiting

  • Institut Bergonié

    Bordeaux, France · Not yet recruiting

  • CHRU Brest

    Brest, France · Not yet recruiting

  • Centre Francois Baclesse

    Caen, France · Not yet recruiting

  • CHU Henri Mondor

    Créteil, France · Not yet recruiting

  • Centre Georges-François Leclerc

    Dijon, France · Not yet recruiting

  • CHU Grenoble

    Grenoble, France · Not yet recruiting

  • Centre Léon Berard

    Lyon, France · Not yet recruiting

  • Institut Paoli-Calmettes

    Marseille, France · Recruiting

  • CHRU Nancy

    Nancy, France · Not yet recruiting

  • Centre Antoine Lacassagne

    Nice, France · Not yet recruiting

  • Hôpital Cochin

    Paris, France · Not yet recruiting

  • Hôpital Saint Louis

    Paris, France · Not yet recruiting

  • Institut Curie

    Paris, France · Not yet recruiting

  • Centre Eugène Marquis

    Rennes, France · Recruiting

  • Centre Henri Becquerel

    Rouen, France · Not yet recruiting

  • CHU Rouen

    Rouen, France · Not yet recruiting

  • Institut Curie

    Saint-Cloud, France · Not yet recruiting

  • Institut de Cancérologie de l'Ouest

    Saint-Herblain, France · Not yet recruiting

  • CHU Saint Etienne

    Saint-Priest-en-Jarez, France · Not yet recruiting

  • ICANS

    Strasbourg, France · Not yet recruiting

  • IUCT Oncopole

    Toulouse, France · Not yet recruiting

  • CHRU Tours

    Tours, France · Not yet recruiting

  • Institut de Cancérologie de Lorraine

    Vandœuvre-lès-Nancy, France · Not yet recruiting

  • Gustave Roussy

    Villejuif, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.